14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
BCAT vs ECAT: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, BlackRock Capital Allocation Term Trust (BCAT) captures the overall head-to-head institutional edge over BlackRock ESG Capital Allocation Term Trust (ECAT) on higher Unified Composite conviction (31.0/100 SELL vs. 28.8/100 SELL) after splitting the core matrix 2–1 (led by composite factor balance), while ECAT wins 1–0 across the 6-pillar growth and valuation breakdown. BCAT trades at $12.56 (N/M Forward P/E, N/A operating margin) versus ECAT at $12.08 (N/M Forward P/E, N/A operating margin).
Growth vs. Quality Trade-Off: BCAT earns the overall head-to-head edge with a stronger Unified Composite Score (31.0/100 SELL vs. ECAT 28.8/100 SELL) and 0.71β · 25% Vol risk profile, whereas ECAT leads top-line expansion (N/A YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates.
Defensive Composite Rating Caution: Although BCAT compares more favorably head-to-head, both BCAT (31.0/100 SELL) and ECAT (28.8/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
Technical & Structure Timing Caution: BCAT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 32.5); meanwhile ECAT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on BCAT vs ECAT. Trailing 12-month operating profitability (BCAT N/A vs ECAT N/A) and valuation multiples (BCAT N/M vs ECAT N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Institutional Equity value chain with $1.6B market capitalization and N/A operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ BCAT vs ECAT Key Questions & Quantitative Answers
As of Nov 16, 2026, BlackRock Capital Allocation Term Trust (BCAT) captures the overall head-to-head institutional edge over BlackRock ESG Capital Allocation Term Trust (ECAT) on higher Unified Composite conviction (31.0/100 SELL vs. 28.8/100 SELL) after splitting the core matrix 2–1 (led by composite factor balance), while ECAT wins 1–0 across the 6-pillar growth and valuation breakdown. BCAT trades at $12.56 (N/M Forward P/E, N/A operating margin) versus ECAT at $12.08 (N/M Forward P/E, N/A operating margin). Growth vs. Quality Trade-Off: BCAT earns the overall head-to-head edge with a stronger Unified Composite Score (31.0/100 SELL vs. ECAT 28.8/100 SELL) and 0.71β · 25% Vol risk profile, whereas ECAT leads top-line expansion (N/A YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates. Defensive Composite Rating Caution: Although BCAT compares more favorably head-to-head, both BCAT (31.0/100 SELL) and ECAT (28.8/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: BCAT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 32.5); meanwhile ECAT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
ECAT leads the Growth & Scale pillar: BCAT posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with ECAT at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, BCAT generates N/A in USD-normalized revenue versus N/A for ECAT. In operating R&D and SG&A reinvestment, BCAT deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ECAT.
BCAT and ECAT trade at balanced relative valuation multiples. BCAT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas ECAT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BCAT (N/A ROE) versus ECAT (N/A ROE) capital efficiency.
In options market volatility and institutional positioning, BCAT carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.71β · 25% Vol realized risk). By comparison, ECAT carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.90β · 28% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.